Insmed Incorporated - Common Stock · Transaction Jun 10, 2026 · Filed Jul 7, 2026 · $1,001 to $15,000
XNAS · INSM
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Insmed, Inc.
PHARMACEUTICAL PREPARATIONS
$128.32
Veridion Score
BETAHIGH CONF · 6/6 factorsMon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET · INSM
MethodologyINSM
Insmed, Inc.
Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
45/ 100
Veridion Score
NEUTRAL · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is INSM moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Insmed, Inc.
PHARMACEUTICAL PREPARATIONSListed since
2000
Employees
2K
Country
US
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$128.32
Last session
Day high
$128.32
Last session
Day low
$128.32
Last session
Previous close
$128.32
52W high
$211.41
-39.30% from high
52W low
$91.88
30% of range
Market cap
$27B
Beta
0.67
Shares out
218.4M
Avg volume
2.9M
VWAP
$128.32
Last session
Price history computed in-house
1W
-3.21%
1M
+18.46%
3M
+18.91%
1Y
+0.83%
YTD
-26.27%
SMA 50 $108.19 · above
SMA 200 $145.31 · below
52W position 30%
INSM overview
Related filings and maps
Public disclosures
Congress activity in INSM
Official filing ↗
1 JTInsmed Incorporated - Common Stock · Transaction Jun 1, 2026 · Filed Jul 7, 2026 · $1,001 to $15,000
INSM · Transaction Oct 3, 2025 · Filed Nov 18, 2025 · $1,001 to $15,000
Gilbert CisnerosSell
INSM · Transaction Sep 22, 2025 · Filed Oct 10, 2025 · $1,001 to $15,000
Gilbert CisnerosSell
INSM · Transaction Aug 8, 2025 · Filed Sep 12, 2025 · $1,001 to $15,000
Federal contracts
INSM contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for INSM in this window.
Lobbying spend
INSM lobbying filings, year to date.
Registered lobbying filings matched to Insmed, Inc..
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for INSM in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for INSM.
Options
Sovereign unlock shows live options positioning for INSM.